

10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids

Hiroaki Gotoh, Katharine K. Duncan, William M. Robertson, and Dale L. Boger*

Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States

S Supporting Information

ABSTRACT: A study on the impact of catharanthine C10 and C12 indole substituents on the biomimetic Fe(III)-mediated coupling with vindoline led to the discovery and characterization of two new and substantially more potent derivatives, 10'-fluorovinblastine and 10'-fluorovincristine. In addition to defining a pronounced and unanticipated substituent effect on the biomimetic coupling, fluorine substitution at C10', which minimally alters the natural products, was found to uniquely enhance the activity 8-fold against both sensitive (IC_{50} = 800 pM, HCT116) and vinblastine-resistant tumor cell lines (IC_{50} = 80 nM, HCT166/VM46). As depicted in the X-ray structure of vinblastine bound to tubulin, this site resides at one end of the upper portion of the T-shaped conformation of the tubulin-bound molecule, suggesting that the 10'-fluorine substituent makes critical contacts with the protein at a hydrophobic site uniquely sensitive to steric interactions.

KEYWORDS: 10'-Fluorovinblastine, 10'-fluorovincristine, synthesis, vinca alkaloids, vinblastine, vincristine

• improved derivatives (R = F)
of vinblastine and vincristine

Compd	IC_{50} (nM)	
	L1210	HCT116
R' = Me (vinblastine)		
R = F	0.7	0.8
R = H	6.0	6.8

R' = CHO (vincristine)		
R = F	0.8	1.5
R = H	6.0	7.0

Vinblastine (**1**) and vincristine (**2**) represent the most widely recognized members of the vinca alkaloids as a result of their clinical use as antitumor drugs (Figure 1).^{1–5}




Figure 1. Natural products.

Originally isolated in trace quantities from *Cantharanthus roseus* (L.) G. Don,^{1–3} their biological properties were among the first to be shown to arise from inhibition of microtubule formation and mitosis that today is still regarded as one of the more successful drug targets for the treatment of cancer.^{5–15}

We recently utilized a biomimetic Fe(III)-promoted coupling of vindoline (**3**) with catharanthine (**4**) in the total synthesis of vinblastine¹⁶ and reported its extension to the total synthesis of a series of related natural products including vincristine and key analogues.^{17–21} Although mechanistic insights into this



coupling^{17,21–26} and subsequent in situ olefin oxidation^{17,27} have been disclosed in these and earlier studies, the key differences in the diastereoselectivity of the Fe(III)-promoted coupling, producing exclusively the natural C16' diastereomer at 25 °C in aqueous buffer, and the more traditional Polonovski fragmentation^{28–32} (5:1 at –78 °C, 1:1 at 0 °C) or 3-chloroindolenine-based^{33–40} couplings suggest that there are features of the biomimetic coupling reaction that are not yet well understood. Herein, we disclose a study of catharanthine substituent effects on the Fe(III)-mediated coupling reaction that led to the discovery of two new, exciting, and more potent synthetic analogues of **1** and **2**.

The series examined entailed C10 or C12 substitution in catharanthine, para or ortho to the indole NH. Because the C10' position in **1** is a site of oxidative metabolism, producing 10'-hydroxyvinblastine (**14b**),⁴¹ substitution that blocks the formation of such metabolites was viewed as an attribute to such derivatives. More significantly and as depicted in the X-ray structure of vinblastine bound to tubulin (Supporting Information, Figure S1),⁴² this site resides at one end of the upper portion of the T-shaped conformation of the tubulin-bound molecule, suggesting that it makes critical contacts with the protein at a site sensitive to steric interactions. Consequently, we viewed derivatives with modifications at this site especially interesting to examine.^{43,44} Thus, a systematic series of catharanthine substituents was examined

Received: October 9, 2011

Accepted: October 18, 2011

Published: October 18, 2011





Compd	Product (% yield)	IC ₅₀ (nM)		
		L1210	HCT116	HCT116/VM46
R = CN	6b (–) ^e	630	620	>10000
R = I	7b (27%)	55	60	840
R = Br	8b (22%)	8.0	8.6	270
R = Cl	9b (42%)	6.2	7.6	720
R = F	10b (40%)	0.7	0.8	80
R = H	1 (50%)	6.0	6.8	600
R = SMe	11b (31%)	50	50	780
R = Me	12b (40%)	7.8	7.8	600
R = OMe	13b (48%)	670	720	>10000
R = OH	14b (0%)	–	–	–

^aCompound 6a was obtained in 7% (20 vs 2 h). ^bRun in 33% TFE–buffer. ^cAlso obtained in 40% (20 h) or 48% (60 h) vs 29% (2 h). ^dObtained by coupling 10'-t-butyloxycarbonyloxycatharanthine and subsequent TFA deprotection. ^eObtained by Pd-catalyzed cyanation of 7b.

Figure 2. C10 substituent effects.

that would provide not only further insight into the Fe(III)-promoted coupling reaction but also the corresponding vinblastine derivatives for comparative examination (Figure 2).⁴⁵

With notable exceptions, electron-withdrawing substituents were observed to slow or preclude coupling with vindoline, whereas derivatives bearing neutral or electron-donating C10 substituents participated effectively in the reaction (5 equiv of FeCl₃, 0.05 N aq HCl–CF₃CH₂OH 10:1, 25 °C, 2 h). The exceptions were the amine derivatives (15–17) and the phenol 14, which underwent competitive oxidation (*p*-quinodiimine or *p*-quinoinine formation). Moreover, a smooth trend of decreasing yield and rate of coupling was observed with the derivatives bearing electron-withdrawing substituents [H (90%) > F (65%) > Cl, Br, I (ca. 30%) > CN (ca. 5%) > NO₂ (0%)], those bearing neutral and weakly electron-donating substituents coupled exceptionally well [H (90%), Me (95%), and SMe (70%)], and the one derivative containing a strong electron-



Compd	Product (% yield)	IC ₅₀ (nM)		
		L1210	HCT116	HCT116/VM46
R = I	19b (40%)	55	80	910
R = Br	20b (31%)	50	80	910
R = Cl	21b (38%)	330	220	5000
R = F	22b (37%)	50	65	730
R = H	1 (50%)	6.0	6.8	600

Figure 3. C12 substituent effects.

• improved derivatives (R = F) of vinblastine and vincristine

Compd	IC ₅₀ (nM)	
	L1210	HCT116
R' = Me (vinblastine)		
R = F	0.7	0.8
R = H	6.0	6.8
R' = CHO (vincristine)		
R = F	0.8	1.5
R = H	6.0	7.0

Figure 4. 10'-Fluorovincristine and 10'-fluorovinblastine.

donating substituent (OMe, 62%) participated effectively in the reaction. Thus, the overall trends are clear and indicate that electron-deficient substituents slow the rate of coupling, suggesting that it is the catharanthine indole and not the previously suggested tertiary amine^{22,46} that undergoes the initial single-electron oxidation, initiating the biomimetic coupling. The ramifications of these observations on the mechanism of the Fe(III)-mediated coupling and the requisite catharanthine structural features required are the subject of our continuing investigations.

A smaller series of derivatives bearing substituents ortho to the indole NH was also examined and provided similar results (Figure 3). The derivative bearing a strong electron-withdrawing substituent (NO₂) failed to participate in the coupling reaction, 23 containing an oxidizable electron-donating substituent (NH₂) led to products of competitive indole oxidation, and those containing modestly electron-withdrawing substituents participated slower and less effectively in the coupling reaction [H (90%) > F (62%) > Cl, Br, I (30–44%)].





Figure 5. Space-filling model of the 10'-fluoro binding site of **10b** ($R = F$, left) generated by adding the fluorine substituent to the X-ray structure of tubulin-bound vinblastine⁴² ($R = H$, right). Comparison models of **7b–9b** ($R = Cl, Br, \text{ and } I$) are provided in Figure S2 in the Supporting Information and illustrate the unique fit for **10b** ($R = F$) and the increasing destabilizing steric interactions at this site as the substituent size progressively increases.

Without optimization, each derivative containing a C10' or C12' substituent was incorporated into the corresponding vinblastine derivative using the direct oxidation of the corresponding anhydrovinblastine or the one-pot, two-step coupling and oxidation protocol.¹⁷ Analogous to the clear impact of catharanthine substituents on the coupling reaction, their impact on the biological properties of **1** was just as clear. Substitution at C12' was detrimental leading to 10-fold reductions in the potency of the derivatives **19–22**, presumably reflecting destabilizing steric interactions when bound to tubulin (Figure 3). With the provision that polar substituents are not well tolerated, the activity of the vinblastine C10' derivatives **6b–14b** in the cell-based assays (Figure 2) exhibited no apparent relationship with the electronic character of the substituents but rather exhibited activity that correlates with their size and shape [$R = F > H > Cl > Me, Br \gg I, SMe$ (10-fold) \gg CN (100-fold)]. Thus, small hydrophobic C10' substituents are tolerated with one derivative exceeding ($R = F$) and several matching the potency of **1** ($R = H$ vs Cl, Me, Br), whereas those bearing the larger ($R = I, SMe$) or rigidly extended ($R = CN$) substituents proved to be 10–100-fold less potent. Moreover, there is a subtle distinction in the less potent anhydrovinblastine versus vinblastine series, reflecting not only the steric interactions at this site but also their interplay with the disposition of the C20' substituents. The anhydrovinblastine derivatives bearing the small C10' substituents are essentially equipotent with anhydrovinblastine ($R = F > H, Cl, Br, Me$), albeit 10-fold less active than vinblastine, and exhibited a greater tolerance for the larger substituents at this site (e.g., $R = SMe$ and CN but not I). These two positions in the upper subunit of vinblastine (C10' and C20') represent the two ends of the upper portion of the T-shaped conformation of the tubulin-bound molecule that is deeply imbedded in the protein (Figure S1 in the Supporting Information).⁴² Presumably, altering the disposition of the C20' ethyl substituent by converting C20' to a sp^2 versus sp^3 center permits some, but not all, anhydrovinblastine derivatives with the larger C10' substituents to bind tubulin and exhibit biological activity. However, the most striking observation to emerge from the studies was the behavior of 10'-fluorovinblastine (**10b**). Fluorine substitution at C10' substantially enhances the cell-based activity (8-fold) against both sensitive (L1210 and HCT116) and vinblastine-resistant cell lines (HCT116/VM46). This latter feature, which is derived from over-expression of the cell surface drug efflux pump Pgp,^{47,48} typically limits the effectiveness of vinblastine upon resistance release. The more potent activity of **10b** suggests that it

represents an attractive alternative drug for both primary care and secondary treatment upon tumor reemergence.

With a recognition that 10'-fluoro substitution may convey uniquely potent activity to such vinca alkaloids, we additionally prepared 10'-fluorovincristine (**26**) for examination. Thus, Fe(III)-promoted coupling (70%) of synthetic 10-fluorocatharanthine (**10**) with synthetic *N*-demethylvindoline (**24**)¹⁷ and subsequent *in situ* Fe-mediated oxidation provided *N*¹-desmethylvinblastine (**25**), which was formulated to provide synthetic 10'-fluorovincristine (**26**), eq 1. Like 10'-fluorovinblastine, 10'-fluorovincristine (**26**) exhibited exceptional activity in the cell-based assays, inhibiting tumor cell growth 5–8-fold more potently than vincristine itself (Figure 4).



Although the enhanced metabolic stability of the 10'-fluoro derivatives may contribute to the increased potency of 10'-fluorovinblastine and 10'-fluorovincristine, the lack of comparable effects with closely related substituents indicate that an effect unique to fluorine substitution is responsible. We suggest that this is derived from the interaction of a uniquely sized hydrophobic substituent further stabilizing the compound binding with tubulin at a site exquisitely sensitive to steric interactions. Comparison models of **1** and **7–10b** built from the X-ray structure of tubulin-bound vinblastine⁴² illustrate a unique fit for **10b** (Figure 5 and Figure S2 in the Supporting Information).

Although preliminary, an initial *in vivo* examination of 10'-fluorovinblastine against the vinblastine-resistant HCT116/VM46 human colon cancer cell line (ip, dosed ip at 0.01, 0.1, and 0.5 mg/kg) provided 7/10, 5/10, and 5/10 surviving mice after 110 days comparable to the antitumor efficacy that vinblastine exhibited against sensitive HCT116 at the requisite higher dose of 0.5 mg/kg (6/10 surviving mice).⁴⁹

The detailed profiling of 10'-fluorovinblastine and 10'-fluorovincristine is in progress, continued exploration of the mechanism of the Fe(III)-mediated biomimetic coupling of catharanthine and vindoline building on the substituent effects observed herein is underway, as is the continued examination of vinblastine structural features contributing to its properties, and the results of the studies will be reported in due course.^{50–54}

■ ASSOCIATED CONTENT

Supporting Information

Full experimental details. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: boger@scripps.edu.

Funding

We gratefully acknowledge the support of the National Institutes of Health (CA115526 and CA042056). We thank Dr. P. Hellier (P. Fabre) for the gift of catharanthine and vindoline, Professor A. Eschenmoser for insightful discussions, and JSPS (H.G.) for fellowship support. W.M.R. and K.K.D. are Skaggs Fellows.

■ REFERENCES

- (1) Noble, R. L.; Beer, C. T.; Cutts, J. H. Role of chance observations in chemotherapy: *Vinca rosea*. *Ann. N.Y. Acad. Sci.* **1958**, *76*, 882.
- (2) Noble, R. L. *Catharanthus roseus* (*Vinca rosea*) - importance and value of a chance observation. *Lloydia* **1964**, *27*, 280.
- (3) Svoboda, G. H.; Nuess, N.; Gorman, M. Alkaloids of *Vinca rosea* Linn. (*Catharanthus roseus* G. Don.). V. Preparation and characterization of alkaloids. *J. Am. Pharm. Assoc. Sci. Ed.* **1959**, *48*, 659.
- (4) Moncrief, J. W.; Lipscomb, W. N. Structures of leurocristine (vincristine) and vincalkebblastine. X-ray analysis of leurocristine methiodide. *J. Am. Chem. Soc.* **1965**, *84*, 4963.
- (5) Neuss, N.; Nuess, M. N. Therapeutic use of bisindole alkaloids from *catharanthus*. In *The Alkaloids*; Brossi, A., Suffness, M., Eds.; Academic: San Diego, 1990; Vol. 37, p 229.
- (6) Pearce, H. L. Medicinal chemistry of bisindole alkaloids from *catharanthus*. In *The Alkaloids*; Brossi, A., Suffness, M., Eds.; Academic: San Diego, 1990; Vol. 37, p 145.
- (7) Borman, L. S.; Kuehne, M. E. Functional hot spot at the C-20' position of vinblastine. In *The Alkaloids*; Brossi, A., Suffness, M., Eds.; Academic: San Diego, 1990; Vol. 37, p 133.
- (8) Fahy, J. Modifications in the "upper" velbenamine part of the *Vinca* alkaloids have major implications for tubulin interacting activities. *Curr. Pharm. Design* **2001**, *7*, 1181.
- (9) Kuehne, M. E.; Marko, I. Syntheses of vinblastine-type alkaloids. In *The Alkaloids*; Brossi, A., Suffness, M., Eds.; Academic: San Diego, 1990; Vol. 37, p 77.
- (10) Potier, P. Synthesis of the antitumor dimeric indole alkaloids from *catharanthus* species (vinblastine group). *J. Nat. Prod.* **1980**, *43*, 72.
- (11) Kutney, J. P. Biosynthesis and synthesis of indole and bisindole alkaloids in plant cell cultures: a personal overview. *Nat. Prod. Rep.* **1990**, *7*, 85.
- (12) Kutney, J. P. Plant cell cultures and synthetic chemistry – a potentially powerful route to complex natural products. *Synlett* **1991**, 11.
- (13) Kutney, J. P. Plant cell culture combined with chemistry: a powerful route to complex natural products. *Acc. Chem. Res.* **1993**, *26*, 559.
- (14) For recent studies, see Kuehne, M. E.; Bornmann, W. G.; Marko, I.; Qin, Y.; Le Boulluc, K. L.; Frasier, D. A.; Xu, F.; Malamba, T.; Ensinger, C. L.; Borman, L. S.; Huot, A. E.; Exon, C.; Bizzarro, F. T.; Cheung, J. B.; Bane, S. L. Syntheses and biological evaluation of vinblastine congeners. *Org. Biomol. Chem.* **2003**, *1*, 2120.
- (15) Miyazaki, T.; Yokoshima, S.; Simizu, S.; Osada, H.; Tokuyama, H.; Fukuyama, T. *Org. Lett.* **2007**, *9*, 4737.
- (16) Ishikawa, H.; Colby, D. A.; Boger, D. L. Direct coupling of catharanthine and vindoline to provide vinblastine: total synthesis of (+)- and ent-(–)-vinblastine. *J. Am. Chem. Soc.* **2008**, *130*, 420.
- (17) Ishikawa, H.; Colby, D. A.; Seto, S.; Va, P.; Tam, A.; Kakei, H.; Rayl, T. J.; Hwang, I.; Boger, D. L. Total synthesis of vinblastine, vincristine, related natural products, and key structural analogues. *J. Am. Chem. Soc.* **2009**, *131*, 4904.
- (18) Va, P.; Campbell, E. L.; Robertson, W. M.; Boger, D. L. Total synthesis and evaluation of a key series of C5-substituted vinblastine derivatives. *J. Am. Chem. Soc.* **2010**, *132*, 8489.
- (19) Sasaki, Y.; Kato, D.; Boger, D. L. Asymmetric total synthesis of vindorosine, vindoline, and key vinblastine analogues. *J. Am. Chem. Soc.* **2010**, *132*, 13533.
- (20) Kato, D.; Sasaki, Y.; Boger, D. L. Asymmetric total synthesis of vindoline. *J. Am. Chem. Soc.* **2010**, *132*, 3685.
- (21) Tam, A.; Gotoh, H.; Robertson, W. M.; Boger, D. L. Catharanthine C16 substituent effects on the biomimetic coupling with vindoline: preparation and evaluation of a key series of vinblastine analogues. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 6408.
- (22) Vukovic, J.; Goodbody, A. E.; Kutney, J. P.; Misawa, M. Production of 3',4'-anhydrovinblastine: a unique chemical synthesis. *Tetrahedron* **1988**, *44*, 325.
- (23) For additional studies on the Fe(III) coupling to provide anhydrovinblastine, see Szantay, C. Jr.; Balazs, J.; Bolcskei, J.; Szantay, C. Synthesis of *Vinca* alkaloids and related compounds. Part LVI. 15',20'-Anhydrovinblastine borane complex. Structural investigations using NMR methods. *Tetrahedron* **1991**, *47*, 1265.
- (24) Sundberg, R. J.; Hong, J.; Smith, S. Q.; Sabato, M.; Tabakovic, I. Synthesis and oxidative fragmentation of catharanthine analogs. Comparison to the fragmentation-coupling of catharanthine and vindoline. *Tetrahedron* **1998**, *54*, 6259.
- (25) For an analogous electrochemical coupling (0.6 V in buffer; NaBH₄) to provide anhydrovinblastine, see Gunic, E.; Tabakovic, I.; Gasic, M. J. Electrochemical synthesis of anhydrovinblastine. *J. Chem. Soc., Chem. Commun.* **1993**, 1496.
- (26) For an enzymatic coupling, see Sagui, F.; Chirivi, C.; Fontana, G.; Nicotra, S.; Passarella, D.; Riva, S.; Danieli, B. Laccase-catalyzed coupling of catharanthine and vindoline: an efficient approach to the bisindole alkaloid anhydrovinblastine. *Tetrahedron* **2009**, *65*, 312.
- (27) Tan, H.; Sakamoto, N.; Hata, E.; Ishitoku, T.; Kihara, N. U.S. Patent 5037977. Method for production of dimeric alkaloids. (*Chem. Abstr.* **1990**, *113*, 6663).
- (28) Potier, P.; Langlois, N.; Langlois, Y.; Gueritte, F. Partial synthesis of vinblastine-type alkaloids. *J. Chem. Soc., Chem. Commun.* **1975**, 670.
- (29) Langlois, N.; Gueritte, F.; Langlois, Y.; Potier, P. Application of a modification of the Polonovski reaction to the synthesis of vinblastine-type alkaloids. *J. Am. Chem. Soc.* **1976**, *98*, 7017.
- (30) Sundberg, R. J.; Gadamasetti, K. G.; Hunt, P. J. Mechanistic aspects of the formation of anhydrovinblastine by Potier-Polonovski oxidative coupling of catharanthine and vindoline. Spectroscopic observation and chemical reactions of intermediates. *Tetrahedron* **1992**, *48*, 277.
- (31) Kutney, J. P.; Ratcliffe, A. H.; Treasurywala, A. M.; Wunderly, S. Studies on the synthesis of bisindole alkaloids. II. The synthesis of 3',4'-dehydrovinblastine, 4'-deoxovinblastine and related analogues. *Heterocycles* **1975**, *3*, 639.
- (32) Kutney, J. P.; Hibino, T.; Jahngen, E.; Okutani, T.; Ratcliffe, A. H.; Treasurywala, A. M.; Wunderly, S. Total synthesis of indole and dihydroindole alkaloids. IX. Studies on the synthesis of bisindole alkaloids in the vinblastine-vincristine series. The biogenetic approach. *Helv. Chim. Acta* **1976**, *59*, 2858.
- (33) For additional approaches to effecting analogous couplings, see Magnus, P.; Stamford, A.; Ladlow, M. Synthesis of the antitumor bisindole alkaloid vinblastine: diastereoselectivity and solvent effect on

the stereochemistry of the crucial C-15–18' bond. *J. Am. Chem. Soc.* **1990**, *112*, 8210.

(34) Magnus, P.; Mendoza, J. S.; Stamford, A.; Ladlow, M.; Willis, P. Nonoxidative coupling methodology for the synthesis of the antitumor bisindole alkaloid vinblastine and a lower-half analog: solvent effect on the stereochemistry of the crucial C-15/C-18' bond. *J. Am. Chem. Soc.* **1992**, *114*, 10232.

(35) Kuehne, M. E.; Matson, P. A.; Bornmann, W. G. Enantioselective syntheses of vinblastine, leurosidine, vincovaline and 20'-epi-vincovaline. *J. Org. Chem.* **1991**, *56*, 513.

(36) Bornmann, W. G.; Kuehne, M. E. A common intermediate providing syntheses of Ψ -tabersonine, coronaridine, iboxyphylline, ibophyllidine, vinamidine, and vinblastine. *J. Org. Chem.* **1992**, *57*, 1752.

(37) Kuehne, M. E.; Zebovitz, T. C.; Bornmann, W. G.; Marko, I. Three routes to the critical C16'-C14' part relative stereochemistry of vinblastine. Syntheses of 20'-desethyl-20'-deoxyvinblastine, and 20'-desethyl-20'-deoxyvincovaline. *J. Org. Chem.* **1987**, *52*, 4340.

(38) Schill, G.; Priester, C. U.; Windhovel, U. F.; Fritz, H. Eine neue synthese von vinblastine-derivaten iv. Synthese von 20'-deethyl-20'-deoxyvinblastin und 20'-deethyl-20'-deoxyvincovalin über 3,Nb-seco-cleavamin-derivate als Zwischenstufen. *Tetrahedron* **1987**, *43*, 3765.

(39) Yokoshima, S.; Ueda, T.; Kobayashi, S.; Sato, A.; Kuboyama, T.; Tokuyama, H.; Fukuyama, T. Stereocontrolled total synthesis of (+)-vinblastine. *J. Am. Chem. Soc.* **2002**, *124*, 2137.

(40) Kuboyama, T.; Yokoshima, S.; Tokuyama, H.; Fukuyama, T. Stereocontrolled total synthesis of (+)-vincristine. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 11966.

(41) Neuss, N.; Mallett, G. E.; Brannon, D. R.; Mabe, J. A.; Horton, H. R.; Huckstep, L. L. *Vinca* alkaloids XXXII. Microbiological conversions of vincalukoblastine (VLB, vinblastine), an antitumor alkaloid from *Vinca rosea*. *Helv. Chem. Acta* **1974**, *57*, 1886.

(42) Gigant, B.; Wang, C.; Ravelli, R. B. G.; Roussi, F.; Steinmetz, M. O.; Curmi, P. A.; Sobel, A.; Knossow, M. Structural basis for the regulation of tubulin by vinblastine. *Nature* **2005**, *435*, 519.

(43) Voss, M. E.; Ralph, J. M.; Xie, D.; Manning, D. D.; Chen, X.; Frank, A. J.; Leyhane, A. J.; Liu, L.; Stevens, J. M.; Budde, C.; Surman, M. D.; Friedrich, T.; Peace, D.; Scott, I. L.; Wolf, M.; Johnson, R. Synthesis and SAR of *Vinca* alkaloid analogues. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 1245.

(44) Sheng, L. X.; Da, Y. X.; Long, Y.; Hong, L. Z.; Cho, T. P. Synthesis and biological evaluation of C-12' substituted vinflunine derivatives. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4602.

(45) Details of the substrate preparations are in the Supporting Information.

(46) Bergman, J.; Bergman, S.; Lindstrom, J.-O. Oxidation of methyl indole-3-acetate induced by FeCl₃ and secondary amines. *Tetrahedron Lett.* **1989**, *30*, 5337.

(47) Lampidis, T. J.; Kolonias, D.; Podona, T.; Israel, M.; Safa, A. R.; Lothstein, L.; Savaraj, N.; Tapiero, H.; Priebe, W. Circumvention of P-gp MDR as a function of anthracycline lipophilicity and charge. *Biochemistry* **1997**, *36*, 2679.

(48) Perego, P.; De Cesare, M.; De Isabella, P.; Carenini, N.; Beggiolin, G.; Pezzoni, G.; Palumbo, M.; Tartaglia, L.; Prtesi, G.; Pisano, C.; Carminati, P.; Scheffer, G. L.; Zunino, F. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. *Cancer Res.* **2001**, *61*, 6034.

(49) Vielhauer, G. A. Unpublished studies.

(50) Ishikawa, H.; Elliott, G. I.; Velcicky, J.; Choi, Y.; Boger, D. L. Total synthesis of (-)- and ent-(+)-vindoline and related alkaloids. *J. Am. Chem. Soc.* **2006**, *128*, 10596.

(51) Elliott, G. I.; Fuchs, J. R.; Blagg, B. S. J.; Ishikawa, H.; Tao, H.; Yuan, Z.; Boger, D. L. Intramolecular Diels–Alder/1,3-dipolar cycloaddition cascade of 1,3,4-oxadiazoles. *J. Am. Chem. Soc.* **2006**, *128*, 10589.

(52) Choi, Y.; Ishikawa, H.; Velcicky, J.; Elliott, G. I.; Miller, M. M.; Boger, D. L. Total synthesis of (-)- and ent-(+)-vindoline. *Org. Lett.* **2005**, *7*, 4539.

(53) Yuan, Z.; Ishikawa, H.; Boger, D. L. Total synthesis of natural (-)- and ent-(+)-4-desacetoxy-6,7-dihydrovindorosine and natural and ent-minovine: oxadiazole tandem intramolecular Diels–Alder/1,3-dipolar cycloaddition reaction. *Org. Lett.* **2005**, *7*, 741.

(54) Wilkie, G. D.; Elliott, G. I.; Blagg, B. S. J.; Wolkenberg, S. E.; Soenen, D. B.; Miller, M. M.; Pollack, S.; Boger, D. L. Intramolecular Diels–Alder and tandem intramolecular Diels–Alder/1,3-dipolar cycloaddition reactions of 1,3,4-oxadiazoles. *J. Am. Chem. Soc.* **2002**, *124*, 11292.